

1 **Title:** Differences in Skilled Nursing Facility Characteristics and Quality Ratings by Long-Term
2 Care Pharmacy Provider

3 **Running Title:** Skilled Nursing Facility Pharmacies

4 **Authors:** Andrew R. Zullo, PharmD, PhD;^{a,b,c,d} Melissa R. Riester, PharmD;^a Elizabeth M.
5 Goldberg, MD, ScM;^{a,e} Meghan A. Cupp, MPH;^b Sarah D. Berry, MD, MPH;^{f,g} Francesca L.
6 Beaudoin, MD, PhD^{a,b}

7 **Affiliations:** ^aDepartment of Health Services, Policy, and Practice, Brown University School of
8 Public Health, 121 South Main Street, Providence, RI, USA; ^bDepartment of Epidemiology,
9 Brown University School of Public Health, 121 South Main Street, Providence, RI, USA;
10 ^cCenter of Innovation in Long-Term Services and Supports, Providence Veterans Affairs
11 Medical Center, 830 Chalkstone Ave, Building 32, Providence, RI, USA; ^dDepartment of
12 Pharmacy, Rhode Island Hospital, 593 Eddy Street, Rhode Island Hospital, Providence, RI,
13 USA; ^eDepartment of Emergency Medicine, Rhode Island Hospital, 593 Eddy Street, Rhode
14 Island Hospital, Providence, RI, USA. ^fDepartment of Medicine, 330 Brookline Avenue, Beth
15 Israel Deaconess Medical Center, Boston, MA; ^gMarcus Institute for Aging Research, Hebrew
16 SeniorLife, 1200 Centre Street, Boston, MA.

17 **Corresponding Author:** Andrew R. Zullo, PharmD, PhD, Department of Health Services,
18 Policy, and Practice, Brown University School of Public Health, 121 South Main Street, Box G-
19 S121-8, Providence, RI, USA, 02912, Phone: 401-863-6309, Email: andrew_zullo@brown.edu,
20 [Twitter: @andrewzullo](https://twitter.com/andrewzullo).

21 **Funding:** This study was supported by grant R21AG061632 from the National Institute on
22 Aging. Dr. Zullo was also supported by National Institute on Aging grant R01AG065722. Dr.

23 Goldberg is also supported by grant K76AG059983 from the National Institute on Aging. Dr.

24 Beaudoin is also supported by grants from the Centers for Disease Control and Arnold Ventures.

25 **Disclosure of Potential Conflicts of Interest:** Dr. Zullo receives grant funding paid directly to

26 Brown University for collaborative research on the epidemiology of infections and vaccine use

27 among nursing home residents. Dr. Goldberg served on an advisory panel for TerSera

28 Therapeutics, which examines the use of intravenous cetirizine for the treatment of urticaria. The

29 other authors have no relevant conflicts of interest to disclose.

30 **Acknowledgements:** The authors thank Dr. Vincent Mor for his feedback on early versions of

31 the manuscript.

32 **Word, Reference, and Graphics Count:** Abstract, 250/250; Main Text, 2,000/2,000;

33 References, 20/30; Tables/Figures, 3/3; Supplementary Material, 2 Tables, 1 Figure.

34 **Brief Summary:** Two pharmacies may comprise over 90% of the skilled nursing facility post-

35 acute care market. This market concentration may represent a prime opportunity to efficiently

36 improve medication management.

37 **ABSTRACT**

38 **Objectives:** Limited data exist on the U.S. long-term care (LTC) pharmacy market and how
39 skilled nursing facilities (SNFs) may differ by LTC pharmacy provider. We estimated the market
40 shares of two major LTC pharmacies (Omnicare and PharMerica) and assessed if SNF
41 characteristics differ by pharmacy.

42 **Design:** Cross-sectional.

43 **Setting and Participants:** Seventy-five Rhode Island (RI) SNFs that provided post-acute care
44 (PAC) services in 2019.

45 **Methods:** SNF location, structure, staffing measures, and quality ratings were ascertained from
46 publicly available data sources. The LTC pharmacy used by each SNF was compiled by case
47 managers at a RI health system.

48 **Results:** Among 75 SNFs, 32 (43%) were served by Omnicare and 36 (48%) by PharMerica.
49 LASSO logistic regression and random forest models identified 5 key predictors of SNFs
50 selecting PharMerica over Omnicare: number of skilled beds, total number of beds, nursing
51 hours per resident per day, five-star health inspection rating, and average number of residents per
52 day. In a multivariable regression model including 4 predictors (total number of beds excluded
53 due to collinearity), SNFs had a 6% higher prevalence of using Omnicare over PharMerica for
54 every additional 10 skilled beds (Prevalence Ratio 1.06, 95% CI 1.02-1.10).

55 **Conclusions and Implications:** Omnicare and PharMerica comprised over 90% of the SNF
56 PAC market in RI, with Omnicare covering larger facilities. Understanding if these companies
57 serve a similar proportion of SNFs in other U.S. states is necessary to advance future research

58 initiatives and examine how collaborations between SNFs and LTC pharmacy chains may
59 improve medication management in SNFs.

60 **Keywords:** Long-Term Care; Marketing of Health Services; Nursing Homes; Pharmacists;
61 Pharmacy.

62 INTRODUCTION

63 As demand for post-acute care (PAC) continues to increase in the United States, long-term
64 care (LTC) pharmacies play a progressively greater role in skilled nursing facility (SNF) care
65 through the provision of prescription medications, medication management, and other services.
66 Due to evolving payment systems and increasing financial pressure, LTC pharmacies have
67 consolidated through mergers and acquisitions over recent years.¹ This has resulted in two
68 companies dominating the U.S. market—Omnicare Inc. (a wholly owned subsidiary of CVS
69 Health Corporation) and PharMerica Corporation. Although their exact combined market share is
70 unknown, Omnicare and PharMerica may now provide a majority of prescription drugs to U.S.
71 SNFs.¹⁻³

72 The predominance of two LTC pharmacies offers a unique opportunity for policymakers,
73 payors, healthcare executives, researchers, and other healthcare stakeholders to improve
74 medication management and SNF quality of care through collaborative interventions between
75 SNFs and the two LTC pharmacy partners. New programs and clinical pharmacy services could
76 be delivered by the LTC pharmacies to the thousands of SNFs they serve, effectively intervening
77 on a majority of U.S. SNFs. Such programs to optimize medication management are particularly
78 important for SNF residents since polypharmacy is common and an estimated 40% of individuals
79 in SNFs take ≥ 9 medications.⁴⁻⁸

80 The types of SNFs each LTC pharmacy chain serves and the clinical services provided to
81 each facility (beyond medication dispensing) are currently unknown. In the absence of data on
82 how SNFs differ by LTC pharmacy provider, including facility characteristics (e.g., SNF size)
83 and quality ratings, researchers and policymakers are limited in their ability to design
84 collaborative interventions or policies that improve medication management in SNFs. Further,

85 without such information, interventions cannot be tailored to the attributes and unique needs of
86 the SNFs served by each pharmacy.

87 Our objectives were to 1) provide empirical estimates of the market shares of each major
88 LTC pharmacy (Omnicare and PharMerica), and 2) assess if SNFs' structure, staffing, and
89 quality characteristics differ by LTC pharmacy provider. We hypothesized that, based on prior
90 public communications from Omnicare and PharMerica to their investors, 1) Omnicare would
91 serve a larger proportion of SNFs than PharMerica, and 2) the SNFs served by Omnicare would
92 be larger facilities with higher overall five-star quality ratings.

93 **METHODS**

94 Study Design and Data Sources

95 This cross-sectional study linked publicly available SNF-level data from calendar year
96 2019 to private data on the LTC pharmacies used by each SNF in the state of Rhode Island (RI).
97 The Nursing Home Compare website and RI Department of Health Nursing Home Summary
98 Report provided SNF-level information on structure, staffing, and quality for each facility in the
99 state.^{9, 10} Since obtaining accurate information on which LTC pharmacy a SNF uses is
100 challenging, we used RI as an exemplar because we could leverage existing partnerships to
101 accurately ascertain that information. The LTC pharmacy for each SNF was collected by the case
102 managers of a local health system in December 2019. These case managers refer patients to
103 SNFs to receive PAC after an inpatient hospital stay and coordinate care transitions by ensuring
104 that discharge prescriptions are sent to the correct LTC pharmacy. Case managers created the
105 LTC pharmacy list as part of their routine workflow and updated the list at regular intervals.
106 Since 1) a single LTC pharmacy is typically used for all patients receiving PAC within the same
107 SNF and 2) the LTC pharmacy list is essential for operations, all case managers confirmed that
108 data were highly accurate. To verify, the lead investigator (A.R.Z.) called 10 randomly sampled
109 SNFs and spoke with the SNF staff to independently confirm their LTC pharmacy provider. No
110 inaccuracies were identified. All datasets were SNF-level; therefore, this study did not require
111 Institutional Review Board approval.

112 Study Population

113 To maximize generalizability, we included all RI SNFs that provided PAC. Assisted
114 living facilities, facilities that provided only LTC (no PAC), and those without SNF beds were
115 excluded (n= 95).

116 LTC Pharmacies of Interest

117 Our primary interest was whether a SNF contracted with Omnicare versus PharMerica as
118 its LTC pharmacy. We defined this dependent variable in analyses as SNF use of Omnicare
119 versus PharMerica.

120 SNF Characteristics

121 SNF characteristics (enumerated in Supplementary Figure S1) were selected based on
122 their potential to influence the use of Omnicare over PharMerica. Selection of characteristics was
123 informed by statements made by Omnicare and PharMerica to investors and the public,
124 complaints documented by the Federal Trade Commission, and discussions with the case
125 managers at the local health system.¹⁻³ SNF characteristics of interest included location,
126 structure, capacity, occupancy, staffing, and five-star quality ratings.

127 Statistical Analysis

128 We used descriptive statistics to summarize the frequency and prevalence of Omnicare
129 versus PharMerica use among SNFs, then described SNF characteristics overall and stratified by
130 LTC pharmacy provider. To understand how SNF characteristics were associated with use of
131 Omnicare versus PharMerica, we used t-tests for continuous variables and chi-squared tests for
132 categorical variables (or their exact or non-parametric equivalents whenever necessary). To
133 understand which SNF characteristics might be the most important predictors of using one LTC
134 pharmacy over another, we used least absolute shrinkage and selection operator (LASSO)

135 logistic regression models with adaptive selection to select SNF characteristics.^{11, 12} In a stability
136 analysis to test the robustness of our primary LASSO approach, we used random forests with 4-
137 fold cross-validation to identify key predictors, then generated corresponding variable
138 importance plots. Finally, after checking correlations between the key SNF characteristic
139 predictors identified through the LASSO logistic regression and random forest, we specified a
140 final multivariable modified Poisson regression model with robust standard errors to estimate
141 prevalence ratios (PRs) with 95% confidence intervals (95% CIs).¹³

142 **RESULTS**

143 LTC Pharmacy SNF Market Share

144 Of the 75 RI SNFs that provided PAC services in 2019, 68 (91%) were served by
145 Omnicare or PharMerica. Thirty-two of the 75 SNFs (43%) were served by Omnicare and 36
146 (48%) were served by PharMerica. Among the SNFs not served by Omnicare or PharMerica, 4
147 (5%) were served by ProCare LTC, a LTC pharmacy chain serving New England and Mid-
148 Atlantic states, and 3 (4%) were served by White Cross Pharmacy, a LTC pharmacy serving RI
149 and southeastern Massachusetts.

150 Characteristics of SNFs by LTC Pharmacy

151 Overall, the 75 SNFs in the study sample had a median (first quartile, third quartile) of
152 100 (60, 133) total beds, 31 (18, 54) skilled beds, and 91 (55, 124) residents per day (Table 1).
153 Compared to SNFs served by Omnicare, SNFs served by PharMerica had fewer total beds
154 (median, 90 versus 124), fewer skilled beds (median, 20 versus 34), and fewer residents per day
155 (median, 75 versus 105). There were no differences in five-star ratings between SNFs using
156 PharMerica versus Omnicare in bivariable analyses (Table 2). Characteristics for SNFs served by
157 other LTC pharmacies are included in Supplemental Digital Content 1.

158 Identifying Predictors of SNFs Utilizing Omnicare versus PharMerica

159 The LASSO logit identified two key predictors of SNFs selecting Omnicare versus
160 PharMerica: number of skilled beds and health inspection five-star rating. Results from the
161 stability analysis using random forests in the full set (Supplementary Figure S1) of variables
162 were partially consistent with those from the LASSO; the variables with the highest importance

163 scores included number of skilled beds, average number of residents per day, total number of
164 beds, and nursing hours per resident per day.

165 Key Predictors of SNFs Utilizing Omnicare versus PharMerica

166 The final multivariable Poisson model included the union of the two sets of variables
167 identified from the LASSO logit and random forest: number of skilled beds (per 10 bed
168 increase), average number of residents per day (per 10 resident increase), nursing hours per
169 resident per day (per 1-hour increase), and five-star health inspection rating (≥ 3 stars versus < 3
170 stars). Total number of beds was not advanced because it was highly collinear with average
171 number of residents per day (Pearson correlation coefficient= 0.97). In the multivariable model,
172 SNFs had a 6% higher prevalence of using Omnicare versus PharMerica for every additional 10
173 skilled beds in the SNF (PR 1.06, 95% CI 1.02-1.10) (Table 3). No other remarkable differences
174 were observed.

175 **DISCUSSION**

176 In this cross-sectional study of 75 SNFs offering PAC in RI, 32 (43%) SNFs were served
177 by Omnicare and 36 (48%) were served by PharMerica, indicating that these large LTC
178 pharmacy chains comprised 91% of the RI SNF PAC market in 2019. Facilities using Omnicare
179 tended to be larger on average, but SNF staffing and quality ratings did not differ significantly by
180 LTC pharmacy provider. If these companies also serve a majority of SNFs across the U.S., a
181 significant opportunity may exist to improve medication management and SNF care quality on a
182 large scale through partnerships between SNFs and these predominant LTC pharmacies.

183 Interventions delivered pragmatically through LTC pharmacies could improve patient
184 care and clinical outcomes for SNF residents and may also result in added benefits to the SNF in
185 terms of quality measures and cost savings.¹⁴ For example, interventions to monitor
186 antipsychotic prescribing for residents with behavioral symptoms of Alzheimer’s disease and
187 related dementias (ADRD) could promote gradual dose reductions and eventual discontinuation
188 of antipsychotic medications, thereby reducing the risk of potentially severe medication adverse
189 effects.¹⁵ SNFs that successfully deprescribe might also improve their five-star quality rating
190 since antipsychotic use measures are reported through the Nursing Home Compare website and
191 the Five-Star Quality Rating System.^{16, 17} LTC pharmacies may also be ideally positioned to
192 assist with transitions of care between hospitals and SNFs to reduce potentially avoidable
193 hospital readmissions, because many rehospitalizations are medication-related.^{18, 19} Reducing
194 potentially avoidable readmissions is increasingly important since CMS regulations now
195 incentivize SNFs to make quality improvements based on performance on hospital readmission
196 measures.²⁰

197 Understanding how SNF characteristics vary by LTC pharmacy providers and predictors
198 of SNFs selecting one LTC pharmacy provider over another are crucial precursor steps to
199 developing and implementing effective medication management programs that can be embedded
200 in dominant LTC pharmacy chains. Future research programs may wish to customize quality
201 improvement initiatives based on whether the LTC pharmacy chain serves facilities with a
202 greater number of beds or lower quality ratings. To inform which programs and services may be
203 most effective for LTC pharmacies to implement, future research should first examine which
204 clinical pharmacy services are currently available to SNFs (e.g., consultant pharmacist services,
205 programs targeted at certain conditions such as ADRD), how often these services are utilized by
206 SNFs, who provides these services (e.g., LTC pharmacy, pharmacist employed by the SNF), and
207 if the services improve medication-related outcomes and are cost-effective.

208 Finally, understanding the characteristics and predictors of SNFs served by each LTC
209 pharmacy will help address a variety of policy issues. For example, understanding which SNFs
210 each LTC pharmacy serves could inform discussions on new payment and care delivery models
211 for PAC. Additionally, it may be important to examine how continued horizontal and vertical
212 consolidation of LTC pharmacies and SNFs switching from one pharmacy to another affects
213 patient outcomes and Medicare expenditures.²

214 Limitations

215 Our study has at least two key limitations. First, since our study included only RI SNFs,
216 our results may not generalize to the entire U.S. SNF PAC market. The parent company of
217 Omnicare, CVS Health Corporation, is headquartered in RI, which could potentially have
218 impacted Omnicare's market share in the state. Second, our statistical power was limited due to
219 our modest sample size. Despite these limitations, our results provide one of the first estimates of

- 220 the combined market share of Omnicare and PharMerica and predictors of SNFs using one LTC
221 pharmacy chain over another.

222 **CONCLUSIONS AND IMPLICATIONS**

223 This study examined the LTC pharmacy market share in a single state and assessed how
224 SNF characteristics differ by LTC pharmacy provider. Our findings demonstrated that two LTC
225 pharmacy chains dominated the SNF PAC market. The U.S. LTC pharmacy market and the types
226 of clinical services that LTC pharmacies deliver to SNFs beyond medication dispensing should
227 be a focus of future inquiry. Understanding national differences in SNF characteristics by LTC
228 pharmacy provider will help policymakers, payors, researchers, and others to begin to understand
229 the current contribution of LTC pharmacies to SNF quality of care and the potential role for
230 interventions to improve SNF quality related to medications.

231 **REFERENCES**

- 232 1. Oliver K. Active immunity: The aging population will strengthen industry revenue.
233 IBISWorld Industry Report OD5707 Institutional Pharmacies in the US; 2018.
- 234 2. Avalere. *Long-Term Care Pharmacy: the Evolving Marketplace and Emerging Policy*
235 *Issues*. 2015.
- 236 3. *In the Matter of Omnicare, Inc. a corporation*, United States of America Before the
237 Federal Trade Commission, (2012).
- 238 4. Dwyer L, Han B, Woodwell D, EA R. Polypharmacy in nursing home residents in the
239 United States: results of the 2004 National Nursing Home Survey. *Am J Geriatr Pharmacother*.
240 2010;
- 241 5. Zullo AR, Smith RJ, Gutman R, et al. Comparative safety of dipeptidyl peptidase-4
242 inhibitors and sulfonylureas among frail older adults. *Journal of the American Geriatrics Society*.
243 Jul 21 2021;doi:10.1111/jgs.17371
- 244 6. Zullo AR, Lee Y, Lary C, Daiello LA, Kiel DP, Berry SD. Comparative effectiveness of
245 denosumab, teriparatide, and zoledronic acid among frail older adults: a retrospective cohort
246 study. *Osteoporosis international : a journal established as result of cooperation between the*
247 *European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA*.
248 Mar 2021;32(3):565-573. doi:10.1007/s00198-020-05732-2
- 249 7. Zullo AR, Riester MR, Erqou S, Wu WC, Rudolph JL, Steinman MA. Comparative
250 Effectiveness of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme
251 Inhibitors in Older Nursing Home Residents After Myocardial Infarction: A Retrospective
252 Cohort Study. *Drugs & aging*. Oct 2020;37(10):755-766. doi:10.1007/s40266-020-00791-w

- 253 8. Zullo AR, Ofori-Asenso R, Wood M, et al. Effects of Statins for Secondary Prevention
254 on Functioning and Other Outcomes Among Nursing Home Residents. *Journal of the American*
255 *Medical Directors Association*. Apr 2020;21(4):500-507 e8. doi:10.1016/j.jamda.2020.01.102
- 256 9. Medicare.gov. Find & compare nursing homes, hospitals & other providers near you.
257 Accessed July 9, 2021, <https://www.medicare.gov/care-compare/>
- 258 10. State of Rhode Island Department of Health. Nursing Home Quality. Accessed July 9,
259 2021, <https://health.ri.gov/nursinghomes/about/quality/>
- 260 11. Buhlmann P, van de Geer S. *Statistics for High-Dimensional Data: Methods, Theory and*
261 *Applications*. Springer; 2011.
- 262 12. Zou H. The Adaptive Lasso and Its Oracle Properties. *J Am Stat Assoc*.
263 2006;101(476):1418-1429.
- 264 13. Zou G. A modified poisson regression approach to prospective studies with binary data.
265 *American journal of epidemiology*. Apr 1 2004;159(7):702-6. doi:10.1093/aje/kwh090
- 266 14. MHA. Procopio R. The Value of the Long-Term Care Pharmacist in the Delivery and
267 Continuum of Care. Accessed July 29, 2021,
268 [https://www.mhainc.com/uploadedFiles/Content/Resources/MHA%20The%20Value%20of%20t](https://www.mhainc.com/uploadedFiles/Content/Resources/MHA%20The%20Value%20of%20the%20LTC%20Pharmacist%200720-%20final.pdf)
269 [he%20LTC%20Pharmacist%200720-%20final.pdf](https://www.mhainc.com/uploadedFiles/Content/Resources/MHA%20The%20Value%20of%20the%20LTC%20Pharmacist%200720-%20final.pdf)
- 270 15. Levinson D. Medicare atypical antipsychotic drug claims for elderly nursing home
271 residents. Department of Health and Human Services Office of Inspector General; 2011.
- 272 16. Gurwitz J, Bonner A, Berwick D. Reducing Excessive Use of Antipsychotic Agents in
273 Nursing Homes. *JAMA*. 2017;318(2):118-119.
- 274 17. Centers for Medicare & Medicaid Services. Design for Nursing Home Compare Five-Star
275 Quality Rating System: Technical Users' Guide.

- 276 18. Boockvar K, Fishman E, Kyriacou C, Monias A, Gavi S, Cortes T. Adverse events due to
277 discontinuations in drug use and dose changes in patients transferred between acute and long-
278 term care facilities. . *Arch Intern Med*. 2004;164(5):545-550.
- 279 19. Boockvar K, Liu S, Goldstein N, Nebeker J, Siu A, Fried T. Prescribing discrepancies
280 likely to cause adverse drug events after patient transfer. *Qual Saf Health Care*. 2009;18(1):32-
281 36.
- 282 20. 80 FR 46389 Medicare Program; Prospective Payment System and Consolidated Billing
283 for Skilled Nursing Facilities (SNFs) for FY 2016, SNF Value-Based Purchasing Program, SNF
284 Quality Reporting Program, and Staffing Data Collection 46389-46477 (2015).
- 285

286 **Table 1.** Characteristics of Skilled Nursing Facilities Overall and Stratified by Long-Term Care
 287 Pharmacy Provider, 2019.
 288

Characteristic	Overall^a	Omnicare	PharMerica	P-value
Facility N	75	32	36	
County				0.36
Providence	43 (57)	19 (59)	21 (58)	
Kent	11 (15)	5 (16)	6 (17)	
Bristol	5 (7)	3 (9)	0 (0)	
Washington	10 (13)	4 (13)	6 (17)	
Newport	6 (8)	1 (3)	3 (8)	
Beds, All, no., median (Q1, Q3)	100 (60, 133)	124 (61, 149)	90 (60, 120)	0.12
Beds, All, no., mean (SD)	106 (51)	116 (58)	96 (45)	0.12
Beds, Skilled, no., median (Q1, Q3)	31 (18, 54)	34 (22, 57)	20 (15, 43)	0.01
Beds, Skilled, no., mean (SD)	43 (37)	52 (43)	31 (24)	0.01
Average Number of Residents / Day, mean (SD)	95 (47)	101 (52)	87 (42)	0.24
Average Number of Residents / Day, median (IQR)	91 (55, 124)	105 (48, 128)	75 (56, 114)	0.32
Nursing Hours / Resident / Day, mean (SD)	0.84 (0.23)	0.83 (0.23)	0.88 (0.22)	0.32
Nursing Hours / Resident / Day, median (IQR)	0.88 (0.65, 1.03)	0.89 (0.64, 1.03)	0.88 (0.75, 1.03)	0.51
For-Profit Status	15 (20)	5 (16)	9 (25)	0.34
Medicare-certified	75 (100)	32 (100)	36 (100)	1.00
Medicaid-certified	75 (100)	32 (100)	36 (100)	1.00
Secure Dementia Care Unit	30 (40)	11 (34)	16 (44)	0.40
<i>Abbreviations:</i> Q1, first quartile; Q3, third quartile; SD, standard deviation.				
<i>Notes:</i> Characteristics reported as number (percent [%]), unless otherwise specified. ^a Includes the 7 skilled nursing facilities that were served by long-term care pharmacies other than Omnicare and PharMerica. Supplemental Digital Content 1 includes characteristics for skilled nursing facilities served by other long-term care pharmacies.				

289

290 **Table 2.** Five-Star Quality Ratings of Skilled Nursing Facilities Overall and Stratified by Long-
 291 Term Care Pharmacy Provider, 2019.
 292

Characteristic	Overall^a	Omnicare	PharMerica^b	P-value
Facility N	75	32	36	
Staffing, Five-star Rating, mean (SD)	3.5 (1.0)	3.6 (0.9)	3.46 (1.2)	0.51
Staffing, Five-star Rating, median (Q1, Q3)	3 (3, 4)	4 (3, 4)	3 (3, 4)	0.48
Staffing, Five-star Rating				
Much Below Average (One Star)	4 (5)	1 (3)	3 (9)	0.20
Below Average (Two Stars)	4 (5)	1 (3)	1 (3)	
Average (Three Stars)	29 (40)	11 (34)	16 (46)	
Above Average (Four Stars)	23 (32)	15 (47)	7 (20)	
Much Above Average (Five Stars)	13 (18)	4 (13)	8 (23)	
Health Inspections, Five-star Rating, mean (SD)	2.8 (1.4)	2.7 (1.4)	3.0 (1.4)	0.28
Health Inspections, Five-star Rating, median (Q1, Q3)	3 (2, 4)	2 (1.5, 4)	3 (2, 4)	0.28
Health Inspections, Five-star Rating				
Much Below Average (One Star)	17 (23)	8 (25)	7 (20)	0.28
Below Average (Two Stars)	18 (24)	10 (31)	5 (14)	
Average (Three Stars)	13 (18)	3 (9)	9 (26)	
Above Average (Four Stars)	16 (22)	7 (22)	8 (23)	
Much Above Average (Five Stars)	10 (14)	4 (13)	6 (17)	
Quality Measures, Five-star Rating, mean (SD)	3.7 (1.1)	3.7 (1.1)	3.7 (1.1)	0.90
Quality Measures, Five-star Rating, median (Q1, Q3)	4 (3, 5)	4 (3, 5)	4 (3, 5)	0.97
Quality Measures, Five-star Rating				
Much Below Average (One Star)	4 (5)	1 (3)	2 (6)	0.80
Below Average (Two Stars)	6 (8)	3 (9)	3 (9)	
Average (Three Stars)	20 (27)	10 (31)	8 (23)	
Above Average (Four Stars)	22 (30)	8 (25)	13 (37)	
Much Above Average (Five Stars)	22 (30)	10 (31)	9 (26)	
Overall Five-star Rating, mean (SD)	3.3 (1.5)	3.2 (1.5)	3.4 (1.5)	0.67
Overall Five-star Rating, median (Q1, Q3)	3 (2, 5)	3 (2, 5)	4 (2, 5)	0.70
Overall Five-star Rating				
Much Below Average (One Star)	9 (12)	4 (13)	3 (9)	0.86
Below Average (Two Stars)	22 (30)	9 (28)	11 (31)	
Average (Three Stars)	8 (11)	5 (16)	3 (9)	
Above Average (Four Stars)	11 (15)	4 (13)	6 (17)	
Much Above Average (Five Stars)	24 (32)	10 (31)	12 (34)	

Abbreviations: Q1, first quartile; Q3, third quartile; SD, standard deviation.
Notes: Characteristics reported as number (percent [%]), unless otherwise specified. ^aIncludes the 7 skilled nursing facilities that were served by long-term care pharmacies other than Omnicare and

PharMerica. Supplemental Digital Content 1 includes characteristics for SNFs served by other LTC pharmacies. ^bOne of the 36 facilities served by PharMerica was not included in the modeling due to missing data on Five-Star Ratings as a result of its inclusion in the Centers for Medicare and Medicaid Services Special Focus Facility Program, a program reserved for facilities identified as having serious quality issues.

293

294 **Table 3.** Multivariable Associations Between Skilled Nursing Facility Characteristics and Use of
295 Omnicare versus PharMerica as the Long-Term Care Pharmacy, 2019 (N=67^a).
296

Characteristic	Multivariable Prevalence Ratio (95% CI), p-value
Skilled Beds (per 10 bed increase)	1.06 (1.02-1.10), p=0.001
Average Number of Residents / Day (per 10 resident increase)	1.01 (0.95-1.08), p=0.707
Nursing Hours / Resident / Day (per 1-hour increase)	1.38 (0.33-5.71), p=0.658
Health Inspection Five-Star Rating	
One or two stars	1.00 (reference)
Three or more stars	0.61 (0.36-1.04), p=0.070
<i>Abbreviations:</i> CI, confidence interval. <i>Notes:</i> ^a One of the 36 facilities served by PharMerica was not included in the modeling due to missing data on Five-Star Ratings as a result of its inclusion in the Centers for Medicare and Medicaid Services Special Focus Facility Program, a program reserved for facilities identified as having serious quality issues.	

297

